Canton, MA, June 17, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced the deployment of the Berkeley Lights, Inc. Beacon® optofluidic platform for antibody discovery.
Concurrent with this announcement, Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services. AbX Biologics will partner with biopharma companies to provide premium contract research capitalizing on a combination of proprietary in vivo technologies and the Beacon platform. The full AbX Biologics solution is expected to launch in 2020, with beta collaborations beginning Q3 2019. Abveris will continue to provide critical reagent antibody discovery and other antibody-related services.
“We are committed to integrating new and innovative technologies to our expanding suite of antibody discovery capabilities in an effort to continue providing premium services for our partners. We believe that the pioneering technology of the Beacon platform in combination with our own cutting-edge discovery expertise will enable us to deliver development-ready candidates in industry-leading timelines,” said Tracey Mullen, Chief Operating Officer of AbX Biologics and Abveris.
The Beacon platform provides accelerated single-cell screening and high-resolution analysis to identify and isolate antigen-specific antibody-secreting cells in a single day. AbX Biologics will leverage this groundbreaking technology in combination with its proprietary immunization and high-throughput characterization capabilities to provide a streamlined, best-in-class therapeutic antibody discovery offering to its growing customer base.
“We are delighted that Abveris and AbX Biologics have selected the Beacon Platform and our Antibody Discovery workflow for their therapeutic antibody discovery programs,” said Dr. Eric Hobbs, CEO of Berkeley Lights. “Berkeley Lights is driven to help companies accelerate the discovery of the best cells for their unique programs. We believe our work with AbX Biologics will help speed its antibody discovery efforts by screening more potential drug candidates faster, reducing the time from target to high value lead, and ultimately delivering new therapies to market faster.”
Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAbTM hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com
About Berkeley Lights:
Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes workflows and processes for the biotechnology sector to accelerate the design, discovery, development, and delivery of cell-based products. By operating at the intersection of biology, technology and information, our workflows automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. BLI enables the rapid deployment of biology for the production of sustainable and scalable sources of food, therapies, and energy.
The Beacon platform is for Research Use Only. Not for use in diagnostic procedures.
Contact for Abveris: